

FORM 51 – 102F3

MATERIAL CHANGE REPORT

1. **Name and Address of Company**

bioMmune Technologies Inc. (formerly MC Partners Inc.)
300 – 576 Seymour Street
Vancouver, BC V6B 3K1

2. **Date of Material Change**

May 24, 2013 and May 28, 2013

3. **News Release**

A news release dated May 28, 2013 was disseminated through Stockwatch and Market News and was filed via SEDAR on the same day.

4. **Summary of the Material Change**

Biomune Technologies Inc. closed its qualifying transaction and concurrent private placement.

5. **Full Description of the Material Change**

bioMmune Technologies Inc. (formerly MC Partners Inc.) (the “**Company**”), announced that on May 24, 2013 the Company closed its previously announced qualifying transaction with bioMmune Advanced Technologies Inc. (formerly bioMmune Technologies Inc.) (“**bioMmune**” and the “**Qualifying Transaction**” respectively). The Qualifying Transaction was conditionally approved by the TSX Venture Exchange (the “**Exchange**”) on April 17, 2013 and was effected pursuant to a share exchange agreement (the “**Share Exchange Agreement**”) among the Company, bioMmune and its shareholders, pursuant to which the Company acquired all of the issued and outstanding common shares of bioMmune in exchange for 5,600,000 common shares of the Company (the “**Consideration Shares**”). All of the Consideration Shares were deposited into escrow pursuant to the terms of the value securities escrow agreement. Further detailed disclosure is contained in the Company’s filing statement, which is available under the Corporation’s profile on SEDAR at www.sedar.com.

In connection with the Qualifying Transaction, the Company also completed a non-brokered private placement of 10,000,000 units of the Company at a price of \$0.15 per unit for gross proceeds of \$1,500,000 (the “**Financing**”). Each unit consists of one common share of the Company and one common share purchase warrant of the Company (the “**Warrant**”). Each whole Warrant entitles the holder to purchase one additional common share of the Company at a price of \$0.25 for a period of 12 months from the completion of the Financing, subject to an exercise acceleration clause. Under the exercise acceleration clause, which the Company may exercise once the Units are free of resale restrictions and if the Company’s shares are trading at or above a volume weighted average price of \$0.40 for more than 20 trading consecutive days, the

Warrants will expire upon 30 days from the date the Company provides notice in writing to the Warrant holders via a news release. Pursuant to the terms of the Financing, the Company paid to Haywood Securities Inc. a finder's fee of \$100,020 and issued a total of 1,000,200 finder's warrants (each a "**Finder Warrant**"). Each Finder Warrant is exercisable into one common share of the Company for a period of 12 months at a price of \$0.25. The proceeds from the Financing will be added to working capital in furtherance of the Company's business. All securities issued are subject to a hold period expiring on September 25, 2013.

Haywood Securities Inc. also acted as the sponsor for the Qualifying Transaction.

After completion of the Qualifying Transaction and the Financing, the Company has 22,600,000 Common Shares issued and outstanding.

Also, in connection with the Qualifying Transaction, on May 22, 2013 the Company changed its name to "bioMmune Technologies Inc." In addition, on May 24, 2013, each of the current directors and officers of the Corporation, other than Mr. Robin Hutchison, resigned, and Reinhard Gabathuler was appointed the President and Chief Executive Officer, Judi Dalling was appointed the Chief Financial Officer, Robin Hutchison was appointed Executive Chairman, and Craig D. Thomas and J. Michael Hutchison, Q.C. were appointed to the Board of Directors of the Company.

The Company's common shares resumed trading on the Exchange under the ticker symbol "IMU" on May 29, 2013, after the Exchange's conditions for listing were satisfied and the Exchange issued its final exchange bulletin confirming the completion of the Qualifying Transaction, the Financing and its approval of the listing.

6. Reliance on subsection 7.1(2) or (3) of National Instrument 51 – 102

N/A

7. Omitted Information

N/A

8. Executive Officer

Rob Hutchison, Executive Chairman
Phone: (604) 688-6775
Fax: (604) 688-6995

9. Date of Report

June 4, 2013